Background {#Sec1}
==========

The American Academy of Paediatrics recommends that the postnatal nutritional management of very low birth weight (VLBW, birth weight \<1500 g) infants should meet the intrauterine rates of foetal growth, i.e., 15 g/kg/day \[[@CR1]\]. However, despite several efforts in recent years regarding nutritional support of preterm infants, postnatal growth restriction is still common in neonatal intensive care units \[[@CR2]\]. Increasing evidence indicates that adequate postnatal growth is positively associated with better neurodevelopmental outcomes \[[@CR3]\]. Therefore, the prevention of postnatal growth restriction in preterm infants during hospitalization is of the utmost importance.

Breast milk is acknowledged as ideal for the nutritional support of preterm infants because of its several health benefits on immunological, gastrointestinal and neurodevelopmental functions

The implementation of human milk feeding has been associated with improved feeding tolerance, reduced rates of necrotizing enterocolitis, sepsis and retinopathy of prematurity, in addition to promotion of neurocognitive development \[[@CR4]\].

However, although the protein and energy content of breast milk from mothers who delivered prematurely is higher than that from mothers of term infants, preterm milk does not meet the nutritional requirements of preterm infants \[[@CR5]\]. Moreover, inter- and intra variability of breast milk composition is elevated \[[@CR6], [@CR7]\]. To optimize the nutritional composition of maternal milk and provide preterm infants with adequate intake of macronutrients, the addition of commercially available fortifiers, either as a single component or multicomponent, has been advocated. Improved growth rates and nutritional parameters have been reported in preterm infants exclusively fed fortified breast milk compared with preterm infants exclusively fed unfortified breast milk \[[@CR5]\]. However, fortification of breast milk may cause adverse effects, including metabolic acidosis \[[@CR8]\]. With regard to osmolality, the combination of multicomponent and single component fortifiers can cause an increase over the recommended upper limits, thus increasing the risk of gastrointestinal intolerance \[[@CR9], [@CR10]\]. Currently, three strategies of breast milk fortification are available \[[@CR11]\]. Standard fortification is the most commonly used practice of breast milk supplementation, which is based on the addition of a fixed dose of product and assuming a standard composition of breast milk. A second approach, called adjustable fortification, modulates protein supplementation on the basis of blood urea nitrogen levels \[[@CR12]\]. The target fortification strategy is based on the regular analysis of breast milk composition, thus allowing for the provision of adequate individual targeted macronutrients to each infant. In recent years, reports have suggested the benefits of this customized approach on decreasing the variability of maternal milk's macronutrients \[[@CR13]\] and improving growth in preterm infants \[[@CR14], [@CR15]\]. However, studies exploring the efficacy and safety of prolonged targeted fortification compared with standard fortification in VLBW preterm infants are still scarce.

The aim of this study was to assess the growth benefits of targeted breast milk fortification during the hospital stay compared with standard fortification in VLBW preterm infants. The hypothesis was that VLBW preterm infants receiving targeted fortification would show better growth at the time of discharge without adverse effects concerning safety and metabolic tolerance.

Methods {#Sec2}
=======

Study design and subjects {#Sec3}
-------------------------

A prospective interventional study was conducted in the NICU of Mangiagalli Clinic in Milan, Italy. Qualifying infants born between October 2014 and March 2015 were enrolled in the intervention group. Informed written consent was obtained from the parents of the participants before enrolment.

The inclusion criteria were as follows: gestational age \<32 weeks, birth weight \<1500 g and ≥10th percentile according to Fenton**'**s growth chart \[[@CR16]\] and exclusively consuming breast milk during the entire hospital stay. The exclusion criteria were the presence of either congenital or chromosomal abnormalities or conditions that interfere with growth such as chronic lung disease (as defined based on the classification of Jobe and Bancalari \[[@CR17]\]), neurological disorders, metabolic, cardiac and gastrointestinal diseases and/or sepsis, which was defined as a positive blood culture.

A flow chart summarizing the study design is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow chart of the study

Infants admitted to the same institution during the previous 6 months (January to June 2014) and who fulfilled the inclusion criteria of the study comprised the standardized fortification group.

Nutritional practices {#Sec4}
---------------------

The nutritional management at our institution did not undergo major changes from January 2014 up to the intervention period except for the approach to breast milk fortification. According to the internal nutritional procedure of our institution, parenteral nutrition was started immediately after birth in infants in the standardized fortification and the intervention groups and enteral nutrition was administered as soon as possible. Nutritional management was similar in the two groups up to the initiation of breast milk fortification. Parenteral nutrition and minimal enteral feeding was started on the first day of life in all infants. The parenteral solutions were prepared by the hospital pharmacy according to the prescription. The solutions contained a minimum of 57 kcal/kg/day with 2.5 g/kg of protein on the first day of life and up to 90--100 kcal/kg/day and 4 g/kg/day of protein within the first week \[[@CR18]\].

In both groups, fortification of breast milk was started when the enteral intake reached 90 ml/kg/day. The volume of enteral feeding was increased based on the infants' cardio-respiratory stability and gastrointestinal tolerance.

Milk fortification {#Sec5}
------------------

Infants in the intervention group received individualized targeted fortification. To enhance feeding tolerance, targeted fortification was gradually introduced over a 3-day period. On day 4, the full amount of the targeted fortification for each macronutrient was prescribed. The intervention period lasted until the infant was discharged.

Mothers of enrolled infants collected expressed milk in sterile bottles. Every monday and thursday at 7 a.m., nurses mixed a bottle containing the milk collected during the previous 24 h using a vortex shaker. Approximately 2 ml of breast milk from each bottle was aliquoted for the macronutrient analysis. Prior to composition analysis, samples of native breast milk were frozen \[[@CR19]\]. After 24 h, the thawed milk was homogenized using an ultrasonic homogenizer (Sonicator^®^, Uppsala, Sweden). Analyses were performed using a human milk analyser (Miris AB^®^, Uppsala, Sweden) based on mid-infrared transmission spectroscopy. The instrument was calibrated for breast milk measurements using the Kjeldahl method for proteins, HPLC for lactose and the Rose-Gottlieb method for fat \[[@CR19]\].

The breast milk analyses were conducted twice a week because this measurement frequency has been reported to adequately compensate the daily nutritional variability of breast milk and to ensure a correct mean target of nutrient intake \[[@CR20]\]. To comply with the guidelines from the European Society for Paediatric gastroenterology, Hepatology, and Nutrition (ESPGHAN) \[[@CR21]\], the target levels of breast milk macronutrients were as follows: 3 g/100 ml of protein, 8.8 g/100 ml of carbohydrates, and 4.4 g/100 ml of fat.

The calculations for target fortification was performed in two steps. First, the macronutrient content of native breast milk was assessed. The additional protein, fat and carbohydrate levels were then calculated on the basis of the ESPGHAN recommendations after subtracting the native breast milk composition in terms of protein, carbohydrates and fat content. The calculated amount of fortifiers was immediately added before the milk was consumed. The following commercially available powdered fortifiers were used: Infant Vita BMF (Dietetic Metabolic Food SRL, Limbiate, Milano, Italy: 48 g protein/100 g, 22 g fat/100 g, 0,47 carbohydrate/100 g); Aptamil BMF (Milupa, Friedrichsdorf, Germany: 25 g protein/100 g, 61 g carbohydrate/100 g); Nidex (Nestlé, Vevey, Switzerland: maltodextrin, 96 g/100 g); Aptamil PS (Milupa, Friedrichsdorf, Germany: 82 g protein/100 g). In the standardized fortification group, the milk had not been analysed; thus, the standard composition of breast milk (protein 1.1 g/100 ml, carbohydrates 7 g/100 ml, and lipids 4.1/100 ml) \[[@CR7]\] was assumed. A fixed dose of fortifier was added to the breast milk according to the manufacturer's instructions. Upon initiation of fortification, the full amount of fortifier was used. The following commercially available powdered fortifiers were used for the standardized fortification group: Aptamil BMF (Milupa, Friedrichsdorf, Germany) and FM85 (Nestlé, Vevey, Switzerland: 20 g protein/100 g, 66 g carbohydrate/100 g). The study period of human milk fortification up until the time of discharge was considered for comparison with the intervention group.

Data collection and growth assessment {#Sec6}
-------------------------------------

Neonatal characteristics of the intervention group (gestational age, weight, length and head circumference) were prospectively recorded. For the standardized fortification group, the data were calculated retrospectively from the patients' computerized medical charts.

Gestational age was based on the last menstrual period and first-trimester ultra sonogram. Weight, length, and head circumference were measured according to standard procedures by the same trained nurse \[[@CR22]\]. Weight was assessed daily, whereas the length and head circumference were assessed weekly. Infant mass was measured on an electronic scale accurate to the nearest 0.1 g; body length was measured to the nearest 1 mm on a Harpenden neonatometer (Holtain Ltd, UK), and head circumference to the nearest 1 mm using a non-stretch measuring tape. The changes in weight, length and head circumference were calculated weekly.

The daily growth rate was calculated from the start of fortification until discharge and was calculated using an exponential regression model as follows:$$\documentclass[12pt]{minimal}
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Osmolality, metabolic assessments and gastrointestinal tolerance of target fortification {#Sec7}
----------------------------------------------------------------------------------------

The osmolality of the unfortified and targeted fortified breast milk was measured using a freezing point osmometer (Osmometer MIR 300-P, E. Mires, Milan, Italy) before milk administration to the infants. Blood parameters (urea nitrogen n.v. 15--38 mg/dl, creatinine n.v. 0.1--0.7 mg/dl, albumin n.v. 3.8--5.4 g/dl, calcium n.v. 8.40--10.20 mg/dl, phosphorus n.v. 2.7--6.7 mg/dl and alkaline phosphates n.v. \<300 U/L levels) were monitored weekly.

Clinical features, including signs of feeding intolerance (e.g., gastric residual volume \>50 % of the previous feeding volume, abdominal distension, enteral feeding interruption, and emesis episodes) and stool frequency, were evaluated daily for each infant.

Statistical analysis {#Sec8}
--------------------

Descriptive data were reported as the mean (standard deviation) (95 % confidence interval), and the significance level was set at 0.05. The sample size was estimated using the daily growth rate. The mean growth rate of the infants fed standard fortified breast milk in our unit was estimated as 12 ± 3 g/kg/day. With a sample size equal to ten and assuming an increase of 3 g/kg/day in the daily growth of infants receiving target fortification compared with standard fortification, the targeted fortification would have resulted in a growth rate of 15 g/kg/day (95 % CI 12.9--17.1). For analysis, inter-group differences in the growth parameters and the daily growth velocity were evaluated using the Mann--Whitney U-test. Statistical analysis was performed using the SPSS version 20 software (Inc, Chicago, IL).

Results {#Sec9}
=======

Ten preterm infants (5 females, 5 males) were enrolled in the intervention group. The standardized fortification group comprised ten preterm infants (4 females, 6 males). The basic characteristics of the enrolled infants in the two groups were similar at birth and at time of enrolment (Table [1](#Tab1){ref-type="table"}). No significant difference in the baseline characteristics between groups was detected.Table 1Baseline characteristics of the two infant groups at birth and at time of enrolmentBirthIntervention\
group Mean (SD)Standardized fortification\
group Mean (SD)p valueGestational age (weeks)29.1 (1.03)29.5 (1.18)0.5Weight (g)1223 (195)1287 (190)0.8Length (cm)37.2 (3.09)38.5 (2.26)0.3Head circumference (cm)26.7 (2.84)27.8 (1.83)0.5*Enrolment*Gestational age (weeks)31.4 (0.97)32.2 (0.63)0.1Weight (g)1412 (231)1557 (173)0.3Length (cm)38.5 (3.4)40.2 (2.1)0.3Head circumference (cm)27.3 (2.03)28.2 (1.13)0.5

The duration of parenteral nutrition (days) and the day of postnatal life on which enteral feeding was begun were similar in the intervention and standardized fortification groups (20.2 ± 6.7 vs 19.2 ± 5.6, 0.75 ± 0.89 vs 1.1 ± 1.05, respectively). Beginning of fortification (days), full enteral feeding achievement (days) and end of intervention (days) did not differ among groups (16.1 ± 3.0 vs 15.9 ± 3.0, 24.2 ± 7.3 vs 26.8 ± 7.6 and 43.7 ± 7.9 vs 42 ± 9.8, respectively). By the fifth day after fortification, infants in both groups achieved similar feeding volumes (160 ± 6.1 ml/kg/day for intervention group vs 162 ± 11.2 ml/kg/day for standardized fortification group) that were unchanged up until time of discharge. The postmenstrual age (weeks) at time of discharge was similar in the intervention (37 ± 1.6) and the standardized fortification groups (36.8 ± 1.5). The time frame during which human milk was fortified both in the intervention and in the standardized fortification groups was similar and lasted 4--7 weeks. For the intervention group, a total of 118 samples from 24-hour pooled breast milk were analysed. The mean macronutrient content of native breast milk of each enrolled infant is shown in Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}.Fig. 2Mean protein (p) content (g/100 ml) of native breast milk of each enrolled subject (S)Fig. 3Mean fat (f) content (g/100 ml) of native breast milk of each enrolled subject (S)Fig. 4Mean carbohydrate (c) content (g/100 ml) of native breast milk of each enrolled subject (S)

The variation of macronutrient content in breast milk before and after targeted fortification is shown in Fig. [5](#Fig5){ref-type="fig"}. For native breast milk, average protein content ranged from 1.1 to 1.8 g/100 ml, average fat content from 4.1 to 5.0 g/100 ml and average carbohydrate content from 5.0 to 6.8 g/100 ml.Fig. 5Average protein (**a**), fat (**b**) and carbohydrate (**c**) content (g/100 ml) in native breast milk (A) and targeted breast milk (B)

On average, in order to meet ESPGHAN recommendations, 1.4 ± 0.1 g of protein, 2.3 ± 0.5 g of carbohydrate and 0.3 ± 0.1 g of fat per 100 ml were added.

Preterm infants fed targeted fortified breast milk showed better growth compared with preterm infants who received standard fortified breast milk. Specifically, the weekly increase in weight, length, head circumference and daily growth rate were higher in the infants in the intervention group. The weight and length at discharge tended to be higher in the intervention group than in the standardized fortification group, whereas the length of stay and head circumference at time of discharge were similar (Table [2](#Tab2){ref-type="table"}).Table 2Outcomes of the intervention and standardized fortification groupsIntervention group Mean (95 % CI)Historical group Mean (95 % CI)p valueWeekly weight increase (grams)205.5 (177--233)155 (132--178)0.025\*Weekly length increase (cm)1.6 (1.1--2.2)1.1 (0.8--1.5)0.003\*Weekly head circumference increase (cm)1.0 (0.9--1.1)0.9 (0.8--1.0)0.03\*Daily growth velocity (g/kg/day)15.7 (14.5--16.9)12.3 (10.7--13.9)0.005\*Length of stay (days)51 (42.9--59.1)45.5 (40.4--50.6)0.475Weight at discharge (grams)2404.3 (2157.9--2650.7)2085.5 (1911.8--2259.2)0.07Length at discharge (cm)45.9 (44.2--47.6)44 (43.1--44.9)0.07Head circumference at discharge (cm)32.2 (31.4--33.1)31.4 (30.6--32.2)0.161\* Statistically significant

The infants enrolled in the intervention group showed an adequate metabolic tolerance (urea nitrogen 18 ± 1.2 mg/dl, creatinine 0.3 ± 0.2 mg/dl, albumin 4.2 ± 0.6 mg/dl, calcium 9.40 ± 0.2 mg/dl, phosphorus 3.2 ± 1.8 mg/dl and alkaline phosphates 258 ± 39 U/L levels). In addition, no signs of gastrointestinal intolerance were observed in the infants in the intervention group. The osmolality values (mOsm/kg) of the breast milk were 300 ± 16 before fortification and 376 ± 66 after fortification.

Discussion {#Sec10}
==========

Our preliminary findings suggest that individualized targeted fortification leads to better growth in preterm infants compared with standard fortification without impairing gastrointestinal and metabolic tolerance. On the basis of human milk analysis, the combined addition of single and multicomponent fortifiers allowed the infants in the intervention group to receive the recommended level of each macronutrient according to ESPGHAN guidelines. Targeted fortification considers the variability of macronutrients of native breast milk and, as a result, limits the risk of macronutrient under-intake \[[@CR13]\]. Under-intake may have occurred in the standardized fortification group when using standard fortification, resulting in inadequate growth. Human milk protein content after standard fortification may fail to meet the recommended intake for preterm infants \[[@CR24]\]. Similarly, probably due to the large variation in the nutritional value of human milk, poor growth rates have been reported in infants fed standardly fortified human milk \[[@CR13], [@CR25]\].

Although the infants in the intervention group showed a higher growth rate compared with infants in the standardized fortification group (with a tendency to achieve higher weight and length at time of discharge), the length of hospital stay was similar between the groups. This result is not surprising if we consider that time of discharge is influenced by other clinical conditions, such as the stability of vital parameters, the achievement of independent oral feeding and adequate coordinated sucking abilities.

In recent years, data regarding the benefits of targeted fortification on preterm infant growth have been reported by other authors. Reali et al. \[[@CR26]\] showed that the use of targeted fortification led to improved growth rates in a cohort of extremely low birth weight infants (i.e., gestational age ≤30 weeks) in the absence of adverse events. The authors specifically reported a mean daily growth rate of 16.04 g/kg/day, which is higher than the mean weight increase observed in the present study. However, when considering the growth rate of infants with a gestational age comparable with that of the infants enrolled in the present study, the adjusted rate was 14.4 ± 0.75 g/kg/day. Rochow et al. \[[@CR14]\] sought to compare the growth pattern of 10 VLBW infants (i.e., gestational age \<32 weeks) who were fed breast milk fortified with targeted fortification for at least 3 weeks with a group of infants fed with breast milk fortified according to standard procedure, but they did not observe any significant differences in the daily growth rate between the two groups (19.9 ± 2.7 vs 19.7 ± 3.3 g/kg/day). The authors speculate that as the feeding volumes of infants fed with standard fortification were significantly higher than those of infants in the targeted fortification group, greater benefits regarding weight gain might have been observed if similar feeding volumes were provided in the targeted fortification group. McLeod et al. \[[@CR27]\] compared the effect of targeted fortification in a group of preterm infants on growth velocity in comparison to standard fortification and did not find any difference among groups (11.4 ± 1.4 vs 12.1 ± 1.6 g/kg/day). Of note, growth velocity in both groups was lower than recommended (15 g/kg/day) \[[@CR1]\].

One strength of our study is that the effect of the targeted fortification was assessed throughout the entire hospital stay, allowing us to gain further insight into the safety and prolonged benefits of targeted fortification on the growth of VLBW preterm infants. The study is limited by the relatively small number of enrolled infants, although it should be considered that the treatment period is relatively long (4--7 weeks, mean 5.6 ± 0.9 weeks). The limited number of subjects is partly due to the strict inclusion criteria, which aimed to exclude the conditions that could negatively interfere with growth. Furthermore, in our NICU, despite the recognized benefits of breast milk on several critical neonatal outcomes, the percentage of infants exclusively fed breast milk is relatively low, in agreement with data from several Italian NICUs \[[@CR28]\]. Because this was a single centre study, the findings cannot be generalized; however, it should be noted that the findings were not influenced by any inconsistency of NICU nutritional management.

Conclusions {#Sec11}
===========

These results indicate the feasible implementation of targeted fortification in clinical neonatal practice, although targeted fortification implies an extra workload for health care professionals.

However, this fortification strategy promotes adequate preterm infants weight gain during hospital stay. Considering the beneficial effects of limiting the postnatal growth retardation on later neurodevelopmental and health outcomes, implementation of targeted fortification of breast milk could contribute to the reduction of the burden of long-term adverse outcomes associated with prematurity.

Further randomized controlled studies are necessary to confirm our results and better explore the efficacy and safety of targeted fortification on long-term growth, with particular focus on infants at increased risk for retarded postnatal growth, such as infants with the lowest birth weights and/or affected by comorbidities.

VLBW

:   very low birth weight

NICU

:   neonatal intensive care unit
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